Document:

I, Linden Boyne, certify that:

1. I have reviewed this annual report on Form 10-KSB of Bioaccelerate Inc (FKA
Westminster Medical Inc);

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: October 14, 2003

                                       /s/ Linden Boyne
                                       -----------------------
                                       Linden Boyne
                                       Secretary and DirectorCERTIFICATIONS

                          I, Basil Parker, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Bioaccelerate Inc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: October 15, 2003

                                        /s/ Basil Parker
                                        -------------------------------------
                                        Basil Parker
                                        President & DirectorI, Linden Boyne, certify that:

1. I have reviewed this quaterly report on Form 10-QSB of Bioaccelerate Inc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: October 15, 2003

                                       /s/ Linden Boyne
                                       -----------------------
                                       Linden Boyne
                                       Secretary and DirectorExhibit 10.9

THESE  SECURITIES  HAVE NOT BEEN  REGISTERED  WITH THE  SECURITIES  AND EXCHANGE
COMMISSION  OR THE  SECURITIES  COMMISSION  OF ANY  STATE  IN  RELIANCE  UPON AN
EXEMPTION  FROM  REGISTRATION  UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"SECURITIES ACT"), AND, ACCORDINGLY,  MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE  REGISTRATION  STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN  AVAILABLE   EXEMPTION  FROM,  OR  IN  A  TRANSACTION  NOT  SUBJECT  TO,  THE
REGISTRATION   REQUIREMENTS  OF  THE  SECURITIES  ACT  AND  IN  ACCORDANCE  WITH
APPLICABLE  STATE  SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO
THE  TRANSFEROR  TO SUCH  EFFECT,  THE  SUBSTANCE  OF WHICH SHALL BE  REASONABLY
ACCEPTABLE TO THE COMPANY.  THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A
BONA FIDE MARGIN  ACCOUNT WITH A REGISTERED  BROKER-DEALER  OR OTHER LOAN WITH A
FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a)
UNDER THE SECURITIES ACT.

                          COMMON STOCK PURCHASE WARRANT

                  To Purchase 385,530 Shares of Common Stock of

                           Health Sciences Group, Inc.

                  THIS COMMON STOCK PURCHASE  WARRANT  CERTIFIES that, for value
received,  Spencer Trask Ventures,  Inc. (the "HOLDER"),  is entitled,  upon the
terms and subject to the limitations on exercise and the conditions  hereinafter
set forth, at any time on or after August 8, 2003 (the "INITIAL  EXERCISE DATE")
and on or prior to the close of business on the fifth anniversary of the Initial
Exercise Date (the "TERMINATION DATE") but not thereafter,  to subscribe for and
purchase  from  Health  Sciences  Group,  Inc.,  a  Colorado   corporation  (the
"COMPANY"),  up to 385,530  shares (the "WARRANT  SHARES") of Common Stock,  par
value $.001 per share, of the Company (the "COMMON  STOCK").  The purchase price
of one share of Common Stock (the "EXERCISE  PRICE") under this Warrant shall be
$1.10  subject to  adjustment  hereunder.  The Exercise  Price and the number of
Warrant  Shares  for  which the  Warrant  is  exercisable  shall be  subject  to
adjustment as provided herein.  Capitalized terms used and not otherwise defined
herein  shall  have  the  meanings  set  forth  in  those  certain  Subscription
Agreement(s) (the "SUBSCRIPTION  AGREEMENT"),  dated August 8, 2003, between the
Company and the signatories thereto.

                  1. TITLE TO WARRANT. Prior to the Termination Date and subject
to compliance with  applicable laws and Section 7 of this Warrant,  this Warrant
and all rights hereunder are transferable, in whole or in part, at the office or
agency of the  Company by the Holder in person or by duly  authorized  attorney,
upon surrender of this Warrant  together with the Assignment Form annexed hereto
properly  endorsed.  The transferee shall sign an investment  letter in form and
substance reasonably satisfactory to the Company.

                  2.  AUTHORIZATION  OF SHARES.  The Company  covenants that all
Warrant  Shares  which may be issued upon the  exercise of the  purchase  rights
represented  by  this  Warrant  will,  upon  exercise  of  the  purchase  rights
represented by this Warrant, be duly authorized,  validly issued, fully paid and
nonassessable and free from all taxes, liens and charges in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

                  3. EXERCISE OF WARRANT.

                           (a) Except as provided in Section 4 herein,  exercise
         of the purchase  rights  represented by this Warrant may be made at any
         time or times on or after the  Initial  Exercise  Date and on or before
         the Termination Date by the surrender of this Warrant and the Notice of
         Exercise  Form  annexed  hereto  duly  executed,  at the  office of the
         Company  (or such  other  office  or agency  of the  Company  as it may
         designate by notice in writing to the registered  Holder at the address
         of such Holder  appearing on the books of the Company) and upon payment
         of the Exercise Price of the shares thereby  purchased by wire transfer
         or  cashier's  check  drawn  on a United  States  bank or by means of a

<PAGE>

         cashless  exercise  pursuant  to  Section  3(c),  the  Holder  shall be
         entitled to receive a certificate  for the number of Warrant  Shares so
         purchased.   Certificates  for  shares  purchased  hereunder  shall  be
         delivered to the Holder within three (3) Trading Days after the date on
         which this Warrant shall have been exercised as aforesaid. This Warrant
         shall  be  deemed  to have  been  exercised  and  such  certificate  or
         certificates  shall be deemed to have been  issued,  and  Holder or any
         other person so  designated to be named therein shall be deemed to have
         become a holder of record of such  shares for all  purposes,  as of the
         date the  Warrant has been  exercised  by payment to the Company of the
         Exercise Price and all taxes required to be paid by the Holder, if any,
         pursuant to Section 5 prior to the issuance of such  shares,  have been
         paid. If the Company  fails to deliver to the Holder a  certificate  or
         certificates  representing  the Warrant Shares pursuant to this Section
         3(a) by the third  Trading  Day after  the date of  exercise,  then the
         Holder will have the right to rescind such exercise.

                           (b) If this  Warrant  shall  have been  exercised  in
         part, the Company shall,  at the time of delivery of the certificate or
         certificates  representing  Warrant  Shares,  deliver  to  Holder a new
         Warrant  evidencing  the rights of Holder to purchase  the  unpurchased
         Warrant  Shares called for by this Warrant,  which new Warrant shall in
         all other respects be identical with this Warrant.

                           (c) This Warrant may also be  exercised,  at any time
         prior to the  Termination  Date,  by means of a "cashless  exercise" in
         which the Holder  shall be  entitled to receive a  certificate  for the
         number of Warrant  Shares  equal to the  quotient  obtained by dividing
         [(A-B) (X)] by (A), where:

                  (A) = the closing bid price on the trading day  preceding  the
         date of such election;

                  (B)     = the Exercise Price of the Warrants, as adjusted; and

                  (X)     = the number of Warrant Shares  issuable upon exercise
                          of the Warrants in  accordance  with the terms of this
                          Warrant.

                  4.      NO FRACTIONAL SHARES OR SCRIP. No fractional shares or
scrip  representing  fractional shares shall be issued upon the exercise of this
Warrant.  As to any fraction of a share which Holder would otherwise be entitled
to purchase  upon such  exercise,  the Company  shall pay a cash  adjustment  in
respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price.

                  5.      CHARGES, TAXES AND EXPENSES.  Issuance of certificates
for Warrant  Shares shall be made without  charge to the Holder for any issue or
transfer  tax or other  incidental  expense in respect of the  issuance  of such
certificate,  all of which taxes and expenses shall be paid by the Company,  and
such  certificates  shall be issued in the name of the Holder or in such name or
names as may be  directed by the Holder;  PROVIDED,  HOWEVER,  that in the event
certificates  for Warrant  Shares are to be issued in a name other than the name
of the Holder,  this Warrant when  surrendered for exercise shall be accompanied
by the  Assignment  Form attached  hereto duly  executed by the Holder;  and the
Company may require, as a condition thereto,  the payment of a sum sufficient to
reimburse it for any transfer tax incidental thereto.

                  6.      CLOSING  OF  BOOKS.  The  Company  will not  close its
stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

                  7.      TRANSFER, DIVISION AND COMBINATION.

                           (a)  Subject  to  compliance   with  any   applicable
         securities  laws and the  conditions  set forth in  Sections 1 and 7(e)
         hereof,  this Warrant and all rights  hereunder  are  transferable,  in
         whole or in part,  upon  surrender  of this  Warrant  at the  principal
         office  of the  Company,  together  with a written  assignment  of this
         Warrant  substantially in the form attached hereto duly executed by the
         Holder  or its  agent  or  attorney  and  funds  sufficient  to pay any
         transfer  taxes  payable  upon the making of such  transfer.  Upon such
         surrender and, if required, such payment, the Company shall execute and
         deliver  a new  Warrant  or  Warrants  in the name of the  assignee  or
         assignees and in the  denomination or  denominations  specified in such
         instrument of assignment, and shall issue to the assignor a new Warrant
         evidencing  the  portion  of this  Warrant  not so  assigned,  and this

                                       2
<PAGE>

         Warrant shall promptly be cancelled.  A Warrant,  if properly assigned,
         may be  exercised  by a new holder for the  purchase of Warrant  Shares
         without having a new Warrant issued.

                           (b) This  Warrant  may be  divided or  combined  with
         other Warrants upon presentation  hereof at the aforesaid office of the
         Company,  together  with a  written  notice  specifying  the  names and
         denominations  in which new  Warrants  are to be issued,  signed by the
         Holder or its agent or  attorney.  Subject to  compliance  with Section
         7(a),  as to any  transfer  which may be involved  in such  division or
         combination,  the  Company  shall  execute and deliver a new Warrant or
         Warrants  in  exchange  for the  Warrant or  Warrants  to be divided or
         combined in accordance with such notice.

                           (c) The Company shall  prepare,  issue and deliver at
         its own expense (other than transfer taxes) the new Warrant or Warrants
         under this Section 7.

                           (d) The Company agrees to maintain,  at its aforesaid
         office,  books for the registration and the registration of transfer of
         the Warrants.

                           (e) If, at the time of the  surrender of this Warrant
         in connection  with any transfer of this Warrant,  the transfer of this
         Warrant shall not be registered  pursuant to an effective  registration
         statement  under  the  Securities  Act  and  under   applicable   state
         securities or blue sky laws, the Company may require, as a condition of
         allowing  such  transfer  (i) that the  Holder  or  transferee  of this
         Warrant,  as the case may be, furnish to the Company a written  opinion
         of  counsel  (which  opinion  shall be in  form,  substance  and  scope
         customary  for opinions of counsel in comparable  transactions)  to the
         effect that such  transfer may be made without  registration  under the
         Securities Act and under  applicable state securities or blue sky laws,
         (ii) that the holder or  transferee  execute and deliver to the Company
         an investment  letter in form and  substance  acceptable to the Company
         and (iii) that the transferee be an "accredited investor" as defined in
         Rule 501(a) promulgated under the Securities Act.

                  8. NO RIGHTS AS SHAREHOLDER UNTIL EXERCISE.  This Warrant does
not entitle the Holder to any voting rights or other rights as a shareholder  of
the Company prior to the exercise hereof. Upon the surrender of this Warrant and
the  payment  of the  aggregate  Exercise  Price  (or  by  means  of a  cashless
exercise),  the Warrant Shares so purchased  shall be and be deemed to be issued
to such Holder as the record owner of such shares as of the close of business on
the later of the date of such surrender or payment.

                  9. LOSS,  THEFT,  DESTRUCTION  OR MUTILATION  OF WARRANT.  The
Company  covenants  that upon  receipt  by the  Company of  evidence  reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
or any stock  certificate  relating to the Warrant Shares,  and in case of loss,
theft or  destruction,  of indemnity or security  reasonably  satisfactory to it
(which, in the case of the Warrant,  shall not include the posting of any bond),
and upon surrender and  cancellation  of such Warrant or stock  certificate,  if
mutilated,  the Company will make and deliver a new Warrant or stock certificate
of like  tenor and dated as of such  cancellation,  in lieu of such  Warrant  or
stock certificate.

                  10.  SATURDAYS,   SUNDAYS,  HOLIDAYS,  ETC.  If  the  last  or
appointed  day for the  taking  of any  action  or the  expiration  of any right
required or granted herein shall be a Saturday,  Sunday or a legal holiday, then
such action may be taken or such right may be exercised  on the next  succeeding
day not a Saturday, Sunday or legal holiday.

                  11.  ADJUSTMENTS  OF  EXERCISE  PRICE AND  NUMBER  OF  WARRANT
SHARES.

                  (a) The number  and kind of  securities  purchasable  upon the
exercise of this Warrant and the Exercise  Price shall be subject to  adjustment
from  time to time  upon  the  happening  of any of the  following.  In case the
Company  shall  (i)  pay a  dividend  in  shares  of  Common  Stock  or  make  a
distribution  in shares of Common  Stock to  holders of its  outstanding  Common
Stock,  (ii)  subdivide  its  outstanding  shares of Common Stock into a greater
number of shares,  (iii) combine its  outstanding  shares of Common Stock into a

                                       3
<PAGE>

smaller  number  of  shares of Common  Stock,  or (iv)  issue any  shares of its
capital  stock in a  reclassification  of the Common  Stock,  then the number of
Warrant  Shares  purchasable  upon  exercise of this Warrant  immediately  prior
thereto  shall be adjusted  so that the Holder  shall be entitled to receive the
kind and number of Warrant  Shares or other  securities  of the Company which it
would  have  owned or have  been  entitled  to  receive  had such  Warrant  been
exercised in advance  thereof.  Upon each such adjustment of the kind and number
of Warrant  Shares or other  securities  of the  Company  which are  purchasable
hereunder,  the Holder  shall  thereafter  be entitled to purchase the number of
Warrant Shares or other securities resulting from such adjustment at an Exercise
Price per Warrant Share or other security  obtained by multiplying  the Exercise
Price in effect  immediately  prior to such  adjustment by the number of Warrant
Shares  purchasable  pursuant  hereto  immediately  prior to such adjustment and
dividing  by the number of Warrant  Shares or other  securities  of the  Company
resulting from such  adjustment.  An adjustment  made pursuant to this paragraph
shall  become  effective  immediately  after the  effective  date of such  event
retroactive to the record date, if any, for such event.

                  (b) EXERCISE PRICE ADJUSTMENT.  (i) If the Company at any time
while this  Warrant is  outstanding  shall  issue,  or be deemed to have issued,
Additional Shares of Common Stock (as hereinafter defined) without consideration
or for  consideration  per share of Common  Stock less than the then  applicable
Exercise  Price (the  "Dilutive  Price")  (a  "Triggering  Issuance")  in effect
immediately  prior to such  issuance,  then forthwith upon the occurrence of any
such event (the  "Dilutive  Event") the Exercise  Price shall be reduced so that
the Exercise Price in effect immediately following the Dilutive Event will equal
the Dilutive  Price.  Upon each adjustment of the Exercise Price pursuant to the
provisions of this Section 11(b), the number of Warrant Shares issuable upon the
exercise  of this  Warrant  shall be  adjusted  to the  nearest  full  amount by
multiplying a number equal to the Exercise Price in effect  immediately prior to
such  adjustment by the number of Warrant  Shares  issuable upon exercise of the
Warrants  immediately  prior to such  adjustment  and  dividing  the  product so
obtained by the adjusted Exercise Price.

                  (c) As used herein:

                           "Additional  Shares of Common  Stock"  shall mean all
                           shares of Common  Stock issued or deemed to be issued
                           by the Company after the date hereof which  represent
                           a  Triggering  Issuance.  If the  Company  issues any
                           Options or  Convertible  Securities  (as  hereinafter
                           defined),  the  maximum  number  of  shares of Common
                           Stock  issuable  thereunder,  shall be  deemed  to be
                           Additional  Shares of Common  Stock  issued as of the
                           time of such issue, if the consideration per share of
                           such   Additional   Shares   of   Common   Stock  (as
                           hereinafter  determined) is less than then-applicable
                           Exercise  Price,  until such time as such  Options or
                           Convertible   Securities   shall   terminate   or  be
                           exercised or converted into Common Stock,  upon which
                           time the  number of shares of Common  Stock  actually
                           thereupon  issued  shall be deemed  to be  Additional
                           Shares of Common  Stock.  The Company shall be deemed
                           to have issued the maximum number of shares of Common
                           Stock   potentially   underlying   any   Options   or
                           Convertible    Securities.     Notwithstanding    the
                           foregoing,  no issuance or deemed issuance nor Common
                           Stock or options or warrants to purchase Common Stock
                           issued to (i) officers,  directors or employees of or
                           consultants   to   the   Company   pursuant   to  any
                           compensation  agreement,  plan or  arrangement or the
                           issuance  of Common  Stock upon the  exercise  of any
                           such options or warrants,  provided  such  securities
                           were issued prior to the date hereof or pursuant to a
                           stock  option plan that was  approved by the board of
                           directors (ii) upon  conversion of the Company Series
                           A  Convertible   Preferred  Stock  or  conversion  of
                           existing convertible securities outstanding as of the
                           date  hereof;  (iii)  upon  exercise  of  outstanding
                           warrants  existing  as of the  date  hereof  or  this
                           warrant;  and  (iv)  in  connection  with a  business
                           acquisition  where the  stockholders  of the  Company
                           prior  to  such  acquisition  own  50% or more of the
                           Common   Stock   of  the   Company   following   such
                           acquisition,  or to an  institution or bank lender in
                           connection  with  a  loan  transaction  or  equipment
                           lease,  shall be deemed the  issuance  of  Additional
                           Shares of Common Stock.

                           "Options"  shall mean rights,  options or warrants to
                           subscribe for,  purchase or otherwise  acquire either
                           Common Stock or Convertible Securities.

                                       4
<PAGE>

                           "Convertible  Securities" shall mean any evidences of
                           indebtedness,  shares  (other than  Common  Stock) or
                           other securities  directly or indirectly  convertible
                           into or exchangeable for Common Stock.

                           With respect to Options and  Convertible  Securities,
                           "Consideration"  per  share of  Additional  Shares of
                           Common  Stock shall be  determined  by adding (x) the
                           aggregate consideration received upon issuance of the
                           Options  or  Convertible  Securities  divided  by the
                           number  of shares  receivable  upon the  exercise  or
                           conversion  thereof  and  (y)  the  minimum  possible
                           consideration  per share  received per share upon the
                           exercise,  conversion  or exchange of such Options or
                           Convertible Securities for shares of Common Stock.

                  12. REORGANIZATION, RECLASSIFICATION, MERGER, CONSOLIDATION OR
DISPOSITION  OF  ASSETS.  In case the  Company  shall  reorganize  its  capital,
reclassify  its  capital  stock,  consolidate  or  merge  with or  into  another
corporation  (where the Company is not the surviving  corporation or where there
is a change in or distribution with respect to the Common Stock of the Company),
or sell, transfer or otherwise dispose of all or substantially all its property,
assets or business  to another  corporation  and,  pursuant to the terms of such
reorganization,   reclassification,  merger,  consolidation  or  disposition  of
assets, shares of common stock of the successor or acquiring corporation, or any
cash,  shares of stock or other securities or property of any nature  whatsoever
(including  warrants or other subscription or purchase rights) in addition to or
in lieu of  common  stock of the  successor  or  acquiring  corporation  ("OTHER
PROPERTY"),  are to be received by or distributed to the holders of Common Stock
of the Company,  then the Holder shall have the right thereafter to receive,  at
the option of the Holder, upon exercise of this Warrant, the number of shares of
Common Stock of the successor or acquiring  corporation or of the Company, if it
is the surviving corporation,  and Other Property receivable upon or as a result
of such reorganization,  reclassification,  merger, consolidation or disposition
of  assets by a Holder of the  number of shares of Common  Stock for which  this
Warrant is  exercisable  immediately  prior to such  event.  In case of any such
reorganization,   reclassification,  merger,  consolidation  or  disposition  of
assets, the successor or acquiring corporation (if other than the Company) shall
expressly  assume the due and punctual  observance  and  performance of each and
every covenant and condition of this Warrant to be performed and observed by the
Company  and all the  obligations  and  liabilities  hereunder,  subject to such
modifications  as may be deemed  appropriate  (as  determined  in good  faith by
resolution  of the Board of  Directors  of the  Company) in order to provide for
adjustments of Warrant Shares for which this Warrant is exercisable  which shall
be as nearly  equivalent as practicable to the adjustments  provided for in this
Section 12. For purposes of this Section 12,  "common  stock of the successor or
acquiring  corporation"  shall  include stock of such  corporation  of any class
which is not  preferred  as to dividends or assets over any other class of stock
of such  corporation  and which is not  subject  to  redemption  and shall  also
include any evidences of indebtedness, shares of stock or other securities which
are convertible into or exchangeable for any such stock,  either  immediately or
upon the arrival of a specified  date or the happening of a specified  event and
any warrants or other rights to  subscribe  for or purchase any such stock.  The
foregoing  provisions  of this Section 12 shall  similarly  apply to  successive
reorganizations,  reclassifications,  mergers,  consolidations or disposition of
assets.

                  13.  VOLUNTARY  ADJUSTMENT BY THE COMPANY.  The Company may at
any time during the term of this Warrant reduce the then current  Exercise Price
to any  amount  and for any period of time  deemed  appropriate  by the Board of
Directors of the Company.

                  14.  NOTICE OF  ADJUSTMENT.  Whenever  the  number of  Warrant
Shares or number or kind of securities or other  property  purchasable  upon the
exercise of this Warrant or the Exercise Price is adjusted,  as herein provided,
the Company  shall give notice  thereof to the Holder,  which notice shall state
the number of Warrant Shares (and other securities or property) purchasable upon
the exercise of this Warrant and the Exercise  Price of such Warrant Shares (and
other  securities  or property)  after such  adjustment,  setting  forth a brief
statement  of  the  facts  requiring  such  adjustment  and  setting  forth  the
computation by which such adjustment was made.

                                       5
<PAGE>

                  15. NOTICE OF CORPORATE ACTION. If at any time:

                           (a) the Company shall take a record of the holders of
         its  Common  Stock  for the  purpose  of  entitling  them to  receive a
         dividend  or  other  distribution,  or any  right to  subscribe  for or
         purchase any evidences of its indebtedness,  any shares of stock of any
         class or any other  securities  or  property,  or to receive  any other
         right, or

                           (b) there shall be any capital  reorganization of the
         Company,  any reclassification or recapitalization of the capital stock
         of the Company or any  consolidation  or merger of the Company with, or
         any sale, transfer or other disposition of all or substantially all the
         property, assets or business of the Company to, another corporation or,

                           (c)  there  shall  be  a  voluntary  or   involuntary
         dissolution, liquidation or winding up of the Company;

then,  in any one or more of such  cases (but not in such cases if the rights of
the Holder or holders of Common Stock will not be materially  affected  thereby,
as for  example  in the case of a merger to effect a change  of  domicile),  the
Company shall give to Holder (i) at least 20 days' prior  written  notice of the
date on which a record date shall be selected for such dividend, distribution or
right or for determining  rights to vote in respect of any such  reorganization,
reclassification,    merger,   consolidation,   sale,   transfer,   disposition,
liquidation  or  winding  up,  and (ii) in the case of any such  reorganization,
reclassification,    merger,   consolidation,   sale,   transfer,   disposition,
dissolution,  liquidation  or winding up, at least 20 days' prior written notice
of the date when the same shall take place.  Such notice in accordance  with the
foregoing  clause also shall specify (i) the date on which any such record is to
be taken for the purpose of such dividend,  distribution  or right,  the date on
which the  holders  of Common  Stock  shall be  entitled  to any such  dividend,
distribution or right, and the amount and character  thereof,  and (ii) the date
on which any such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition,  dissolution,  liquidation or winding up is to take place
and the time, if any such time is to be fixed, as of which the holders of Common
Stock shall be entitled to exchange their Warrant Shares for securities or other
property deliverable upon such disposition,  dissolution, liquidation or winding
up. Each such written notice shall be sufficiently  given if addressed to Holder
at the  last  address  of  Holder  appearing  on the  books of the  Company  and
delivered in accordance with Section 18(d).

                  16. AUTHORIZED  SHARES.  The Company covenants that during the
period the Warrant is  outstanding,  it will  reserve  from its  authorized  and
unissued Common Stock a sufficient  number of shares to provide for the issuance
of the  Warrant  Shares  upon the  exercise of any  purchase  rights  under this
Warrant.  The Company further  covenants that its issuance of this Warrant shall
constitute  full  authority  to its  officers  who are charged  with the duty of
executing stock certificates to execute and issue the necessary certificates for
the Warrant Shares upon the exercise of the purchase  rights under this Warrant.
The Company will take all such  reasonable  action as may be necessary to assure
that such Warrant Shares may be issued as provided  herein without  violation of
any applicable law or regulation,  or of any  requirements of the trading market
upon which the Common Stock may be listed.

                  Except  and to the  extent as waived  or  consented  to by the
Holder,  the Company  shall not by any action,  including,  without  limitation,
amending  its  certificate  of  incorporation  or  through  any  reorganization,
transfer  of  assets,  consolidation,  merger,  dissolution,  issue  or  sale of
securities or any other voluntary action,  avoid or seek to avoid the observance
or  performance  of any of the terms of this  Warrant,  but will at all times in
good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or  appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (a) not increase the par value of any Warrant
Shares above the amount payable therefor upon such exercise immediately prior to
such  increase  in par value,  (b) take all such action as may be  necessary  or
appropriate  in order that the Company may validly and legally  issue fully paid
and nonassessable  Warrant Shares upon the exercise of this Warrant, and (c) use
commercially reasonable efforts to obtain all such authorizations, exemptions or
consents from any public regulatory body having  jurisdiction  thereof as may be
necessary to enable the Company to perform its obligations under this Warrant.

                                       6
<PAGE>

                  Before  taking any action which would result in an  adjustment
in the number of Warrant  Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such  authorizations  or exemptions
thereof,  or consents  thereto,  as may be necessary from any public  regulatory
body or bodies having jurisdiction thereof.

                  17. [INTENTIONALLY OMITTED]

                  18.      MISCELLANEOUS.

                           (a)  JURISDICTION.  This Warrant  shall  constitute a
         contract under the laws of New York,  without regard to its conflict of
         law, principles or rules.

                           (b)  RESTRICTIONS.  The Holder  acknowledges that the
         Warrant  Shares  acquired  upon the  exercise of this  Warrant,  if not
         registered,  will have  restrictions  upon resale  imposed by state and
         federal securities laws.

                           (c) NONWAIVER  AND EXPENSES.  No course of dealing or
         any delay or failure to  exercise  any right  hereunder  on the part of
         Holder shall  operate as a waiver of such right or otherwise  prejudice
         Holder's  rights,  powers  or  remedies,   notwithstanding  all  rights
         hereunder  terminate on the Termination  Date. If the Company willfully
         and knowingly fails to comply with any provision of this Warrant, which
         results in any material damages to the Holder, the Company shall pay to
         Holder  such  amounts  as shall be  sufficient  to cover  any costs and
         expenses  including,  but not limited to,  reasonable  attorneys' fees,
         including  those  of  appellate  proceedings,  incurred  by  Holder  in
         collecting  any amounts due pursuant  hereto or in otherwise  enforcing
         any of its rights, powers or remedies hereunder.

                           (d) NOTICES.  Any notice,  request or other  document
         required or  permitted  to be given or  delivered  to the Holder by the
         Company shall be delivered in accordance with the notice  provisions of
         the Subscription Agreement.

                           (e) LIMITATION OF LIABILITY.  No provision hereof, in
         the  absence  of any  affirmative  action by Holder  to  exercise  this
         Warrant or purchase  Warrant Shares,  and no enumeration  herein of the
         rights or  privileges  of Holder,  shall give rise to any  liability of
         Holder for the purchase  price of any Common Stock or as a  stockholder
         of the Company, whether such liability is asserted by the Company or by
         creditors of the Company.

                           (f) REMEDIES.  Holder,  in addition to being entitled
         to exercise all rights granted by law,  including  recovery of damages,
         will be  entitled  to  specific  performance  of its rights  under this
         Warrant. The Company agrees that monetary damages would not be adequate
         compensation  for any loss  incurred by reason of a breach by it of the
         provisions  of this  Warrant and hereby  agrees to waive the defense in
         any  action  for  specific  performance  that a remedy  at law would be
         adequate.

                           (g)  SUCCESSORS  AND ASSIGNS.  Subject to  applicable
         securities laws, this Warrant and the rights and obligations  evidenced
         hereby shall inure to the benefit of and be binding upon the successors
         of the Company and the successors and permitted assigns of Holder.  The
         provisions  of this  Warrant are  intended to be for the benefit of all
         Holders from time to time of this Warrant and shall be  enforceable  by
         any such Holder or holder of Warrant Shares.

                           (h)  AMENDMENT.  This  Warrant  may  be  modified  or
         amended or the provisions hereof waived with the written consent of the
         Company and the Holder.

                           (i) SEVERABILITY.  Wherever possible,  each provision
         of this Warrant shall be  interpreted in such manner as to be effective
         and valid under  applicable  law, but if any  provision of this Warrant
         shall be prohibited by or invalid under  applicable law, such provision

                                       7
<PAGE>

         shall be ineffective  to the extent of such  prohibition or invalidity,
         without  invalidating the remainder of such provisions or the remaining
         provisions of this Warrant.

                           (j)  HEADINGS.  The headings used in this Warrant are
         for the  convenience  of reference only and shall not, for any purpose,
         be deemed a part of this Warrant.

                              ********************

                                       8
<PAGE>

         IN WITNESS WHEREOF,  the Company has caused this Warrant to be executed
by its officer thereunto duly authorized.

Dated:  _____________, 2003
                                     HEALTH SCIENCES GROUP, INC.

                                     By:______________________________________
                                        Name:
                                        Title:

                                       9
<PAGE>

                               NOTICE OF EXERCISE

To:      Health Sciences Group, Inc.

                  (1) The undersigned hereby elects to purchase ________ Warrant
Shares of Health  Sciences  Group,  Inc.  pursuant to the terms of the  attached
Warrant,  and tenders herewith  payment of the exercise price in full,  together
with all applicable transfer taxes, if any.

                  (2) Payment shall take the form of (check applicable box):

                      [ ]  in lawful money of the United States; or

                      [ ]  the  cancellation of such number of Warrant Shares as
                           is  necessary,  in  accordance  with the  formula set
                           forth in  subsection  3(c),  to exercise this Warrant
                           with respect to the maximum  number of Warrant Shares
                           purchasable   pursuant  to  the   cashless   exercise
                           procedure set forth in subsection 3(c).

                  (3) Please issue a certificate  or  certificates  representing
said Warrant  Shares in the name of the  undersigned or in such other name as is
specified below:

                           Name:

                           Address:
                                    ----------------------------------------

                                    ----------------------------------------

                                    ----------------------------------------
                           SS or Tax
                           ID number:
                                    ----------------------------------------

The Warrant Shares shall be delivered to the following:

                           ----------------------------------------

                           ----------------------------------------

                           ----------------------------------------

                                              [Warrant holder]

                                              By:
                                                 ------------------------------
                                                  Name:
                                                  Title:

                                              Dated:
                                                   ----------------------------

<PAGE>

                                 ASSIGNMENT FORM

                        (To assign the foregoing warrant,
                      execute this form and supply required
                                  information.
                  Do not use this form to exercise thewarrant.)

FOR VALUE RECEIVED,  the foregoing  Warrant and all rights evidenced thereby are
hereby assigned to

_______________________________________________ whose address is

---------------------------------------------------------------.

---------------------------------------------------------------

                                        Dated:  ______________, _______

                  Holder's Signature: _____________________________

                  Holder's Address:   _____________________________

                                      -----------------------------

Signature Guaranteed:  ___________________________________________

NOTE: The signature to this  Assignment Form must correspond with the name as it
appears on the face of the Warrant,  without  alteration or  enlargement  or any
change whatsoever,  and must be guaranteed by a bank or trust company.  Officers
of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]